prikaz prve stranice dokumenta Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab
  Preuzmi
PDF 235.58 KB
Znanstveni rad - Prikaz slučaja
Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab
Acta clinica Croatica, 62 (2023), 2; 382-385. https://doi.org/10.20471/acc.2023.62.02.19
Krečak, Ivan; Gverić-Krečak, Velka

Citirajte ovaj rad

Krečak, I. i Gverić Krečak, V. (2023). Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab. Acta clinica Croatica, 62. (2), 382-385. doi: 10.20471/acc.2023.62.02.19

Krečak, Ivan i Velka Gverić Krečak. "Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab." Acta clinica Croatica, vol. 62, br. 2, 2023, str. 382-385. https://doi.org/10.20471/acc.2023.62.02.19

Krečak, Ivan i Velka Gverić Krečak. "Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab." Acta clinica Croatica 62, br. 2 (2023): 382-385. https://doi.org/10.20471/acc.2023.62.02.19

Krečak, I. i Gverić Krečak, V. (2023) 'Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab', Acta clinica Croatica, 62(2), str. 382-385. doi: 10.20471/acc.2023.62.02.19

Krečak I, Gverić Krečak V. Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab. Acta clinica Croatica [Internet]. 2023. [pristupljeno 03.12.2024.];62(2):382-385. doi: 10.20471/acc.2023.62.02.19

I. Krečak i V. Gverić Krečak, "Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab", Acta clinica Croatica, vol. 62, br. 2, str. 382-385, 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:287378. [Citirano: 03.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:287378
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Refractory Guillain-Barré Syndrome in a Patient with Asymptomatic Multiple Myeloma Successfully Treated with Low-Dose Rituximab
Naslov (hrvatski)Refraktorni Guillain-Barreov sindrom u bolesnika s asimptomatskim multiplim mijelomom uspješno liječenim niskom dozom rituksimaba
AutorIvan Krečak
AutorVelka Gverić-Krečak
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Despite being extremely rare, Guillain-Barré syndrome (GBS) has been recognized as a neurological complication of multiple myeloma, with variable responses to plasmapheresis (PEX), intravenous immunoglobulins (IVIG), and anti-myeloma therapies. In this paper, we report a case of a female patient with asymptomatic multiple myeloma (aMM) who initially presented as PEX- and IVIG-refractory GBS. After failure of PEX, IVIG, and anti-myeloma therapy (bortezomib, melphalan, and prednisone), the patient was eventually successfully treated with low-dose rituximab (100 mg/m2 per week in four doses). To the best of our knowledge, this is the first case to report successful treatment of refractory GBS potentially associated to aMM with low-dose rituximab. Additional studies are needed to elucidate the pathophysiological processes and the interplay between the dysregulated immune response, monoclonal immunoglobulin (MG), and neural tissue damage in GBS patients. Also, the potential role of rituximab in the treatment of MG-associated GBS warrants further exploration.
Sažetak (hrvatski)
Guillain-Barréov sindrom (GBS) iznimno rijetko komplicira multipli mijelom. Način liječenja ove neurološke komplikacije u kontekstu multiplog mijeloma nije definiran s obzirom na to da plazmafereza, intravenski imunoglobulini i (imuno) kemoterapije usmjereni na plazmastanični klon polučuju vrlo varijabilne kliničke odgovore. U ovom radu prikazujemo klinički tijek bolesnice s asimptomatskim multiplim mijelomom (aMM) koja se pri dijagnozi prezentirala kao refraktorni GBS. Nakon neuspješnog liječenja plazmaferezom, imunoglobulinima i kemoterapijom (bortezomib, melfalan i prednizon) bolesnicu smo uspješno liječili niskim dozama rituksimaba (100 mg/m2 na tjedan u četiri doze). Koliko nam je poznato, ovo je prvi slučaj u kojem je refraktorni GBS potencijalno povezan s aMM uspješno liječen niskim dozama rituksimaba. Dodatne studije su potrebne kako bi razjasnile patofiziološke procese između monoklonskog imunoglobulina (MG) i oštećenja perifernog živčanog sustava u bolesnika s GBS. Također, uloga rituksimaba u liječenju bolesnika s GBS povezanim s MG zaslužuje dodatna istraživanja.
Ključne riječi (engleski)
Ključne riječi (hrvatski)
Jezikengleski
Jezikhrvatski
Vrsta publikacijeZnanstveni rad - Prikaz slučaja
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaActa clinica Croatica
Brojčani podacivol. 62, br. 2, str. 382-385
p-ISSN0353-9466
e-ISSN1333-9451
DOIhttps://doi.org/10.20471/acc.2023.62.02.19
URN:NBNurn:nbn:hr:184:287378
Datum objave publikacije2023
URL dokumentahttps://hrcak.srce.hr/308847
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2023-10-20 10:06:33